Biotech · Ag-Biotech · Plant Science · Cellular Agriculture

Your results are ready.
Your story doesn’t add up
when it matters most.

Most biotech programs that lose deals, stall partnerships, or miss raises don’t fail because the science was wrong. They fail because the execution infrastructure behind the science could not be defended when it mattered most. Ze-CORE builds that infrastructure — before scrutiny arrives.

Request a Basalt Audit Check your risk signal →

How it works

From conversation to
diligence-grade intelligence.

Let’s talk.

See your risk signal.

Take the Ze-CORE Quick Scan. It gives you an instant view of your highest-risk pillar across data lineage, knowledge resilience, evidence integrity, and governance. Then book a free discovery meeting to review your report and determine if the full Basalt Assessment is the right fit for your program.

Take the Quick Scan →
Build a program ready for scrutiny.

Know before they do.

From data to decision, every claim is traceable, tested, and ready for review. Upon agreement, you are granted access to the Basalt Audit™ platform.

Access the Basalt Audit™ platform →

The process begins with a digital risk assessment, followed by an onsite evaluation led by Prince Zogli and, when needed, a domain-specific expert scientist. Each gap is identified, scored, and classified as Fatal, Serious, or Watchlist. Within two weeks of the onsite evaluation, you receive a comprehensive report with a clear, prioritized remediation plan.

Diligence-ready by design.

Ze-CORE stays until it is stable.

From data to decision, every claim is traceable, tested, and ready for review. Ze-CORE stays with you until the system is stable. We work alongside your team to close every gap identified, coordinating domain-specific experts when needed. Nothing is handed off and left to you alone. After implementation, Ze-CORE Pulse is deployed to monitor progress. Risk closure is verified by both parties before completion. A Performance Readiness Report is then issued for your records.

The problem

The make-or-break moment.
Every founder dreads it.

You have spent two years building something real. The idea and proof of concept are captivating. Your team believes in it and is working hard to make it work. You spent days on the roadshow. Finally, a serious investor or partner is in the room. And then the questions start.

QUESTIONS THAT STALL DEALS
“Can you show us the full data lineage for this result?”
“At what scale did you generate this data — and what is your conversion rate at 10× current volume?”
“Who owns this process if your lead scientist leaves?”

The answers don’t come quickly enough. The investor makes a note. The meeting ends politely. The follow-up is delayed. Not because the idea is weak — but because partners and investors fear the space between a brilliant idea and a reproducible product. Sometimes you receive a report with a polite explanation. Often you never hear why.

⚠
Narratives that collapse — your scientific story holds in a pitch but breaks under technical questioning in the data room.
⚠
Fragmented data — data not FAIR-aligned, results exist but lineage, context, and ownership do not. An investor cannot verify what they cannot trace.
⚠
Irreproducible assays — results that cannot be reproduced across people, environments, or fields. Detected months too late, after the runway is spent and the timeline is broken.
⚠
Knowledge walking out the door — when a key expert leaves, the protocol leaves with them.
⚠
MVPs that don’t show scalability — bench results with no proof of reproducibility at 10× or 100× scale — discovered during a key negotiation, not before it.
⚠
Regulatory gaps found too late — missing SOPs, SOP deviations not captured, or incomplete data packages that surface at an FDA pre-IND meeting, not earlier when there is ample time to fix them.

THIS APPLIES ACROSS BIOTECH · PLANT SCIENCE · CELLULAR AGRICULTURE · APPLIED R&D

This is not rare. This is the pattern.

Investors and partners want to see how your data holds up under pressure. Ze-CORE provides the execution infrastructure that ensures your team doesn’t just discover — it builds decision-ready evidence so your program operates at a diligence-ready standard.

Book a discovery call →
The platform

Ze-CORE is not a report.
It is not a checklist.

Ze-CORE is an embedded R&D execution framework — built by someone who faced the same problem you are facing right now. As technical lead, Ze-CORE’s founder built R&D systems and investor-grade scientific narratives that held up under Series B scrutiny. He has been in the data room. He has been the person answering the questions. He built Ze-CORE because he watched too many scientifically excellent programs lose deals — not because the science was wrong, but because the infrastructure around it was invisible.

Ze-CORE Framework™
A system to make R&D work reproducible, traceable, and decision-ready.
The four parts work in sync to identify and fix deal killers.
01
Basalt™ Audit
Open platform →
Find where your R&D will break under scrutiny.
Gap analysis across reproducibility, data integrity, execution quality, and diligence readiness. Every risk named, graded, and prioritized.
02
Prizm Pipeline™
Turn lab work into traceable, usable, and AI-ready data.
FAIR-aligned data infrastructure from bench to cloud. Version control, metadata, and lineage built in. Audit-ready and AI-ready.
03
MVE Engineering™
Make experiments drive decisions, not activity.
Every experiment linked to a decision. Clear success and failure criteria. Faster cycles, fewer wasted runs, and go/no-go decisions built on evidence.
04
Vector Execution™
Keep the system running consistently.
Cross-functional alignment, clear ownership, and ongoing risk tracking. Systems that run consistently - and scale beyond any single person.
How it works together
• Basalt finds the gaps
• Prizm fixes data and traceability
• MVE fixes how experiments drive decisions
• Vector keeps everything running over time
Sample deliverables
See the format. Understand the depth.
Basalt Audit™

Find where your R&D will break under scrutiny.

A structured onsite and digital evaluation conducted by a PhD-level scientist. The Basalt Audit goes inside your program and surfaces the gaps that investors and regulators find — before they do.

What it does
• Identifies gaps in reproducibility, data integrity, and execution
• Surfaces hidden risks before investors or partners do
• Aligns your internal story with your actual data
What you get
• Ze-CORE Assessment across all four pillars
• Ze-CORE Health Scorecard
• Personalized gap analysis and impact summary
• Ze-CORE Pulse monitoring dashboard
ZE-CORE HEALTH SCORECARD — ILLUSTRATIVE
PRIZM™
Critical
BASALT™
Moderate
MVE™
Moderate
VECTOR™
Strong
Illustrative example · Ze-CORE methodology
Ze-CORE Investor Report™

Independent R&D intelligence for investors and partners.

Ze-CORE partners with investors to surface R&D risk through an onsite Ze-CORE Investor Assessment. The Ze-CORE Investor Intelligence Engine processes assessment data through a weighted risk-scoring algorithm — detecting the execution signals most correlated with program failure and M&A collapse — and delivers independent intelligence on the company.

What you get
• Ze-CORE Investor Score (0–100) with three risk tiers
• 16 monitored risk signals across Fatal, Serious, and Watchlist
• Investment recommendation for the memo
• All four pillar scores with visual breakdown
• Final PDF-ready report — drops straight into the data room
ZE-CORE™ · INVESTOR RISK REPORT · ZC-IR-A4F2C891
Helix Bio · Series A
Investor Risk Report
54
ZE-CORE INVESTOR SCORE
2
FATAL
3
SERIOUS
1
WATCH
• FATAL SIGNAL · S2 — CLAIMS AHEAD OF SUPPORTING DATA
Several core claims rest on single experiments. Independent verification would likely fail to reproduce results at this stage.
Deal condition: Require independent reproducibility audit of top 3 assays before close.
Illustrative example · Ze-CORE methodology
Ze-CORE Pulse™

Our commitment doesn’t end at deployment. It ends at stability.

Upon successful implementation of remediation recommendations, Ze-CORE Pulse activates. Together we establish an agreed-upon Pulse Period — a dedicated window of post-implementation partnership tailored to your specific needs. During this period, Ze-CORE tracks your progress periodically to evaluate, calibrate, and verify that the infrastructure is serving its strategic purpose.

The Pulse Period concludes when we have verified that the risk has been mitigated and issued a final Performance Readiness Report.

• Monthly check-ins with calibrated scoring
• Remediation progress tracking
• Continuous diligence readiness monitoring
• Progress is verified, not assumed — Ze-CORE Pulse includes periodic in-person follow-up visits. Real improvement is confirmed onsite.
• Final Performance Readiness Report
HELIX BIO · PULSE HISTORY · 6 MONTHS
Jan
Feb
Mar
Apr
May
Jun
READINESS IMPROVING
Score moved from 41% to 76% in 6 months. Knowledge drain dimension shows strongest recovery.
Illustrative example · Ze-CORE methodology
Who we serve

Every lab where rigorous
science deserves rigorous execution.

From therapeutic biotech to plant science to ag-biotech - if your program generates data that investors or regulators will scrutinize, Ze-CORE was built for you.

Early-Stage Biotech
Pre-seed through Series B. Drug discovery, cell therapy, biologics, diagnostics. You are building toward an IND or a Series A - and the data package behind it needs to hold. Ze-CORE tells you exactly where it doesn't before an investor does.
Ag-Biotech & Plant Science
Crop science, plant-made pharmaceuticals, sustainable agriculture, gene editing in plants, cultivated protein, and precision fermentation. Your regulatory path is long, your investors need to trust the data trail, and the reproducibility crisis in agricultural science is only beginning to be understood. Ze-CORE maps every execution gap before it costs you a deal.
Cellular Agriculture
Cultivated meat, precision fermentation, cell-based dairy and seafood. Industry analysts project 70–90% of cellular agriculture programs will fail - not because the biology is wrong, but because reproducibility at scale was never built into the infrastructure. If your bioprocess protocol lives in one scientist's head and cannot be reproduced across operators or bioreactor scales, you are not investable yet. Ze-CORE maps that gap and closes it before an investor or regulator does.
Synthetic Biology Startups
Metabolic engineering, biomanufacturing, industrial biotech. You are building organism-level complexity with teams that are small and fast-moving. One departure can collapse months of undocumented protocol knowledge. Ze-CORE closes that gap.
Academic & Translational Labs
University labs, core facilities, and translational research groups with high graduate student and postdoc turnover. Every departure is a knowledge drain. Ze-CORE builds the resilience infrastructure your institution should already have.
Life Science Investors
Ze-CORE partners with seed funds, Series A specialists, and agri-biotech investors to surface R&D risk before the term sheet. Ze-CORE partners with investors to surface R&D risk with an onsite Ze-CORE Investor Assessment - conducted by a PhD-level scientist. The Ze-CORE Investor Report surfaces what the deck never shows and gives you the deal conditions to protect your position.
The difference

What changes when your execution
infrastructure is ready.

With Ze-CORE
✓  The investor opens your data room and finds exactly what they need
✓  Every claim traces to evidence — every evidence traces to its source
✓  Your lead scientist can leave and the assay remains reproducible
✓  The risk gap is found early — not during negotiations
✓  The regulatory package is complete 13 months before the FDA meeting
✓  Your narrative holds under the hardest technical questions
Without it
✗  The follow-up email never comes — and you wonder why
✗  Results cannot be reproduced across people or labs
✗  The partnership stalls while you scramble for documentation
✗  The key scientist leaves — and you lose months in recovery
✗  An irreproducible assay runs 9–12 more months before anyone flags it
✗  The IND filing reveals gaps that needed 18 months to fix
✗  The valuation is cut 30% for “execution risk”
✗  The team shows activity, not decision-grade progress
Services

Straightforward.
Stage-appropriate.

Every engagement starts with a discovery call. No generic assessments - every Ze-CORE audit is contextualized to your stage, indication, and next milestone.

Seed / Pre-seed
Basalt Essentials
On request
A paid Basalt Audit engagement - covering the full four-pillar assessment, Ze-CORE Health Report, and quarterly Pulse check-ins. Every engagement begins with a signed agreement.
  • Four-pillar blind assessment - PRIZM™ · BASALT™ · MVE™ · VECTOR™
  • Ze-CORE Health Report
  • Quarterly Pulse check-ins (4/year)
  • Remediation priority list
  • 30-min results debrief call
Most popular
Series A / B
Basalt Audit + Remediation
On request
The Basalt Audit is a paid engagement. Remediation is a separate, structured engagement that follows - each with its own scope and agreement. The audit tells you exactly where the gaps are. Remediation closes them.
  • Everything in Essentials
  • Monthly Pulse (12/year)
  • Ze-CORE Investor Risk Report
  • Diligence Readiness Certificate
  • Proposal + remediation roadmap
  • Unlimited advisory access for 30 days
VC Funds
Portfolio Intelligence
On request
Ze-CORE partners with you to surface R&D risk through an onsite Ze-CORE Investor Assessment - and monitors portfolio health after. Independent. Rigorous. Investor-grade.
  • Independent R&D risk assessment before you invest
  • PhD-level onsite evaluation - before the company prepares
  • Ze-CORE Investor Risk Report with deal conditions
  • Live portfolio dashboard with Ze-CORE Health Index tracking
  • Benchmark percentile data by stage and sector
  • Priority advisory access with Prince Zogli
Enterprise
Ze-CORE Enterprise
On request
Multi-site deployment for large biotech organizations, research institutions, and portfolio-level engagements requiring systematic, continuous R&D execution intelligence.
  • Multi-site assessment management
  • Enterprise admin portal
  • Benchmark data access by stage and sector
  • Dedicated account management
  • Custom SLA and data governance
  • Portfolio-level Ze-CORE Health Index tracking
Custom
Built for your program
On request
Not every program fits a standard tier. If your situation is unusual - a complex multi-site study, a regulated manufacturing process, a sector outside the core Ze-CORE scope, or a specific milestone with a tight window - this is where we start. We scope the engagement around what you actually need.
  • Scope defined after discovery call - no predetermined deliverable list
  • Single-question audit, deep-dive on one pillar, or full assessment - your choice
  • Flexible timeline and format - remote, on-site, or hybrid
  • Sector-expert partner sourced where needed
  • Fixed-fee engagement - agreed before work begins
Early detection value — case studies

The cost of finding out too late.

These illustrative scenarios are built from real cost structures across salary benchmarks, reagent pricing, CRO rates, and regulatory timeline data. They reflect patterns Ze-CORE was built to prevent. Real client case studies will be added as engagements are completed.

Seed Stage  ·  Cell Line Development
Irreproducible assay detected 9 months too late
A 5-person seed-stage biotech discovers in Month 9 that a critical assay has been producing irreproducible results due to poor experimental controls and absent data lineage documentation - when preparing for Series A diligence. Independent assessment would have flagged the gap by Month 5, before the runway was fully committed.
Detected at Month 9
$234K
Hard costs - 9 months of personnel, reagents, equipment, and crisis remediation
Detected at Month 5
$87K
Hard costs - 5 months of spend before the gap is identified and corrective action begins
Hard cost savings from early detection
$147K
Estimated early detection cost
~5% of loss prevented
Beyond the hard costs: a 3–6 month fundraise delay at seed stage costs $150K–$300K in extended runway burn. Discovering assay flaws during investor diligence signals poor execution discipline — term sheets are pulled or valuation is cut 20–40%. The $70K hard saving understates the real exposure by a factor of 5× or more.
Data lineage failure Data lineage Series A readiness
Illustrative scenario based on published salary benchmarks, reagent pricing, and CRO rate data. Not a specific client. Real case studies will replace these as engagements are completed.
Series A  ·  Manufacturing Scale-Up
Process breaks at 10× volume - undocumented SOPs
A 15-person Series A biotech scaling production discovers their process fails at 10× volume due to batch variability and undocumented standard operating procedures. Discovered in Month 10 during Series B preparation. Independent assessment would have flagged the knowledge resilience gap by Month 5.
Detected at Month 10
$1.01M
Personnel, manufacturing failures, equipment, CRO remediation, emergency consulting - all after scale-up collapse
Detected at Month 5
$344K
Hard costs to Month 5 - protocol gaps identified before scale-up failure compounds
Hard cost savings from early detection
$665K
Estimated early detection cost
~5% of loss prevented
A manufacturing failure discovered during Series B diligence triggers a 30–50% valuation haircut. A pharma partnership on hold for 6 months defers $500K–$1M in milestones. Undocumented process changes create IND filing exposure worth $800K+ in extended pre-clinical costs. The hard savings are real — the strategic exposure is 10× larger.
Knowledge resilience failure Knowledge resilience Scale-up reproducibility
Illustrative scenario based on published salary benchmarks, reagent pricing, and CRO rate data. Not a specific client. Real case studies will replace these as engagements are completed.
Series B  ·  IND Filing Readiness
Regulatory data gaps found 8 months before IND - in crisis mode
A 35-person Series B company discovers critical gaps in their regulatory data package - missing SOPs, incomplete data lineage, reproducibility failures - during an FDA pre-IND meeting. Independent R&D execution assessment, starting at Month 5, would have identified and begun remediation with 13+ months to address gaps before the FDA pre-IND meeting.
Gaps found at FDA pre-IND
$6.94M
Personnel crisis, CRO repeats, 12-month IND delay runway burn ($4.8M), emergency bridge financing
Gaps found at Month 5
$396K
Hard costs to Month 5 - 13 months to remediate before FDA pre-IND meeting, no crisis, no delay
Hard cost savings from early detection
$6.5M
Estimated early detection cost
~6% of loss prevented
A 12-month IND delay cascades to a 24-month delay to Phase 1 completion as patent cliffs approach. In the current market a 12-month Series C delay carries a 60% chance of failing to raise at all. The IND timeline is not a regulatory problem — it is an existential business problem. Ze-CORE exists for this exact moment.
Evidence integrity failure Milestone misalignment IND readiness Data lineage
Illustrative scenario based on published salary benchmarks, CRO rates, regulatory timeline data, and IND filing cost estimates. Not a specific client. Real case studies will replace these as engagements are completed.

These scenarios are built from published cost benchmarks across salary data, reagent pricing, and CRO rates. The numbers reflect what independent early detection is worth - not what Ze-CORE charges. Take the Quick Scan and see your highest-risk pillar in minutes.

See your risk signal now →
About Ze-CORE

Ze-CORE

Ze-CORE was founded by a scientist and strategist who watched good science fail for preventable reasons. Every engagement is led personally - from onsite evaluation to regulatory strategy to data infrastructure.

PZ
Founder & CEO
Prince Zogli
PhD · MBA · PMP

Scientist. Strategist. Builder. Prince holds a science PhD, an MBA with specialization in Business and Financial Analytics, and a PMP. 15 years moving between the bench, the boardroom, and the data room. As technical lead, he built the R&D data infrastructure and investor-grade scientific narratives that anchored a $30M+ Series B close. Ze-CORE exists to address the execution gaps he watched derail scientifically excellent programs and stall partnerships - not because the science was wrong. Ze-CORE is how he ensures that never happens to your program.

“Discovery Rigor by Design. Not as a tagline — as a discipline. Every great discovery deserves execution infrastructure strong enough to defend it. That is what we build.”

- Prince Zogli, Founder & CEO, Ze-CORE
Ready when you are

The negotiation stage is not the moment
to find out.

Due diligence has only one timeline that matters — the one that ends when the investor opens the data room. Everything before that moment is preparation. Everything after is too late.

The Ze-CORE Quick Scan takes minutes. It surfaces your risk instantly. It is the fastest way to know whether your execution infrastructure would survive the questions that matter most.

Take the Ze-CORE Quick Scan → Request a Basalt Audit

Takes minutes · No access code needed · Instant result

Request a Basalt Audit

We review every request personally. You will hear from Prince Zogli within 24 hours. You can also email us directly at hello@ze-core.com

✓

Request received.

Prince Zogli will review your request and be in touch within 24 hours.

Ze-CORE™ · Discovery Rigor by Design.